Thioredoxin signaling as a target for cancer therapy
Garth Powis1, D Lynn Kirkpatrick
1Department of Experimental Therapeutics, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. gpowis@mdanderson.org
Abstract:
Thioredoxin (Trx) family members play critical roles in the regulation of cellular redox homeostasis. Cancer cells exist in a stressed environment and rely on the Trxs for protection against stress-disregulated redox signaling. The most extensively studied member of the family is Trx-1 whose levels are increased in many human cancers most likely in direct response to stress. Trx-1 contributes to many of the hallmarks of cancer including increased proliferation, resistance to cell death and increased angiogenesis. Trx-1 is a validated cancer drug target associated with aggressive tumor growth, resistance to standard therapy and decreased patient survival. A surrogate target for Trx-1 may be thioredoxin reductase (TR). Drugs that inhibit Trx-1 and TR are in clinical development with early promising results.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
